Hims & Hers Health Inc (NYSE: HIMS) Is Worth Evaluating At $21.75

During the last session, Hims & Hers Health Inc (NYSE:HIMS)’s traded shares were 10.17 million, with the beta value of the company hitting 1.07. At the end of the trading day, the stock’s price was $21.75, reflecting an intraday gain of 4.42% or $0.92. The 52-week high for the HIMS share is $21.44, that puts it up 1.43 from that peak though still a striking 74.02% gain since the share price plummeted to a 52-week low of $5.65. The company’s market capitalization is $4.67B, and the average trade volume was 8.39 million shares over the past three months.

Hims & Hers Health Inc (NYSE:HIMS) trade information

Hims & Hers Health Inc (HIMS) registered a 4.42% upside in the last session and has traded in the green over the past 5 sessions. The stock spiked 4.42% in intraday trading to $21.75, hitting a weekly high. The stock’s 5-day price performance is 11.08%, and it has moved by 86.70% in 30 days. Based on these gigs, the overall price performance for the year is 143.02%.

3 Tiny Stocks Primed to Explode The world's greatest investor — Warren Buffett — has a simple formula for making big money in the markets. He buys up valuable assets when they are very cheap. For stock market investors that means buying up cheap small cap stocks like these with huge upside potential.

We've set up an alert service to help smart investors take full advantage of the small cap stocks primed for big returns.

Click here for full details and to join for free

Hims & Hers Health Inc (HIMS) estimates and forecasts

Statistics show that Hims & Hers Health Inc has outperformed its competitors in share price, compared to the industry in which it operates. Hims & Hers Health Inc (HIMS) shares have gone up 144.66% during the last six months, with a year-to-date growth rate more than the industry average at 263.64% against 17.60. In the rating firms’ projections, revenue will increase 38.90% compared to the previous financial year.

As companies strive to predict their financial trajectories, we turn our attention to the forthcoming financial quarter. Here are the insights gathered from industry analysts. Revenue for the current quarter is expected to be 295.35M as predicted by 12 analyst(s). Meanwhile, a consensus of 12 analyst(s) estimates revenue growth to 314.83M by the end of current fiscal year. As per earnings report from last fiscal year’s results, sales for the corresponding quarters totaled 204.96M and 226.7M respectively. In this case, analysts expect current quarter sales to grow by 44.10% and then jump by 38.90% in the coming quarter.

While earnings are projected to return 253.25% in 2024.

HIMS Dividends

Hims & Hers Health Inc is due to release its next quarterly earnings in July. However, it is important to remember that the dividend yield ratio is merely an indicator meant to only serve as guidance.

Hims & Hers Health Inc (NYSE:HIMS)’s Major holders